We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Non-coding Regions of the Genome in Microglia Linked to Alzheimer’s Disease Risk

By LabMedica International staff writers
Posted on 28 Nov 2019
Print article
Image: Immunofluorescence image of microglial cells stained red with antibody. DNA shown in blue (Photo courtesy of Wikimedia Commons)
Image: Immunofluorescence image of microglial cells stained red with antibody. DNA shown in blue (Photo courtesy of Wikimedia Commons)
A recently published paper linked risk of developing Alzheimer’s disease (AD) to enhancers - non-coding DNA regions of the genome - that were present in microglia but not in other types of brain cells such as neurons or astrocytes.

In genetics, an enhancer is a short (50–1500 base pair) region of DNA that can be bound by proteins (activators) to increase the likelihood that transcription of a particular gene will occur. Enhancers can be located up to one million base pairs away from the target gene, upstream or downstream from the start site. There are hundreds of thousands of enhancers in the human genome.

Investigators at the University of California, San Diego (USA) isolated four different kinds of brain cells: neurons, microglia, oligodendrocytes, and astrocytes from six AD patients. The genes in these cells were examined for genetic variations associated with the disease in non-coding enhancer regions of each cell type.

Results revealed that while psychiatric disorders were primarily associated with variants in transcriptional enhancers and promoters in neurons, sporadic AD variants were largely confined to microglia enhancers. Interactome maps (maps of the whole set of molecular interactions in a particular cell) connected disease-risk variants in cell type-specific enhancers to promoters in an extended microglia gene network in AD.

Microglia are a type of neuroglia located throughout the brain and spinal cord. Microglia account for 10 to 15% of all cells found within the brain. As the resident macrophage cells, they act as the first and main form of active immune defense in the central nervous system.

Employing pluripotent human stem cells, the investigators were able to target an enhancer region near BIN1, a gene previously been linked to AD. They found that deleting this enhancer region led to a dramatic reduction in expression of BIN1 in microglia, but not in neurons or astrocytes.

"Focusing on genetic variation associated with Alzheimer's disease (AD), we show preferential enrichment in disease risk variants in enhancers that are selectively active in microglia, the major immune cell in the brain," said senior author Dr. Christopher Glass, professor of cellular and molecular medicine at the University of California, San Diego. "This finding substantially extends prior studies linking microglia to late-onset Alzheimer's disease."

The paper was published in the November, 14, 2019, online edition of the journal Science.

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.